Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

Completed · Phase 3 · NCT05461573

Conditions: Contraception, Change in Bone Mineral Density

Research payments reported, 2025: $1.5M
U.S. investigators named: 44
Sites paid: 32
Planned or actual enrollment: 1,542

About the trial

Sponsor: Insud Pharma (with Chemo Research)
Tested: Drospirenone (drug)
Dates: Started 2022-08-02; completion 2025-05-27
Results posted: Not yet

This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113. The secondary objective of Part A is to evaluate the safety and tolerability of LPRI-CF113. The primary objective of Part B is to evaluate the impact of LPRI-CF113 on bone mineral density (BMD) at the lumbar spine (L1-L4) after 12 months (13 medication cycles). The secondary objective of Part B is to evaluate the impact of LPRI-CF113 on BMD and bone turnover after 12 months (13 medication cycles) at the femoral neck, total hip, and total body.

From ClinicalTrials.gov, last updated 2025-10-08. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Exeltis, USA Inc. reported $1.5M in research payments for this study in 2025 (265 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it